References
1. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N,
Miresmaeili S-M, Bahreini E. A comprehensive review of COVID-19
characteristics. Biological procedures online. 2020;22:1-10.
2. Kerget B, Kerget F, Koçak AO, et al. Are Serum Interleukin 6 and
Surfactant Protein D Levels Associated with the Clinical Course of
COVID-19? Lung. 2020;198(5):777-784.
3. Kerget B, Kerget F, Aksakal A, Aşkın S, Sağlam L, Akgün M. Evaluation
of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels in
COVID‐19 patients with macrophage activation syndrome and acute
respiratory distress syndrome. Journal of Medical Virology. 2020.
4. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in
survivors of severe acute respiratory syndrome and Middle East
respiratory syndrome coronavirus outbreaks after hospitalisation or ICU
admission: a systematic review and meta-analysis. Journal of
Rehabilitation Medicine. 2020;52(5).
5. Park WB, Jun KI, Kim G, et al. Correlation between pneumonia severity
and pulmonary complications in Middle East respiratory syndrome.Journal of Korean medical science. 2018;33(24).
6. Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19
patients at time of hospital discharge. European Respiratory
Journal. 2020;55(6).
7. Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90
patients with COVID-19 pneumonia: a longitudinal study. Radiology.
In:2020.
8. Hui D, Joynt G, Wong K, et al. Impact of severe acute respiratory
syndrome (SARS) on pulmonary function, functional capacity and quality
of life in a cohort of survivors. Thorax. 2005;60(5):401-409.
9. Hui DS, Wong KT, Ko FW, et al. The 1-year impact of severe acute
respiratory syndrome on pulmonary function, exercise capacity, and
quality of life in a cohort of survivors. Chest.2005;128(4):2247-2261.
10. Ngai JC, Ko FW, Ng SS, TO KW, Tong M, Hui DS. The long‐term impact
of severe acute respiratory syndrome on pulmonary function, exercise
capacity and health status. Respirology. 2010;15(3):543-550.
11. McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in
COVID-19 pneumonia related macrophage activation syndrome.Autoimmunity reviews. 2020:102537.
12. Otsuka R, Seino K-i. Macrophage activation syndrome and COVID-19.Inflammation and regeneration. 2020;40(1):1-6.
13. Nusair S. Abnormal carbon monoxide diffusion capacity in COVID-19
patients at time of hospital discharge. European Respiratory
Journal. 2020;56(1).
14. Lagadinou M, Solomou EE, Zareifopoulos N, Marangos M, Gogos C,
Velissaris D. Prognosis of COVID-19: Changes in laboratory parameters.Age (yrs). 2020;62(13.4):47-16.42.
15. Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein
levels and FEV1 decline: a longitudinal population-based study.Respiratory medicine. 2006;100(12):2112-2120.
16. Lee CH, Goag EK, Lee SH, et al. Association of serum ferritin levels
with smoking and lung function in the Korean adult population: analysis
of the fourth and fifth Korean National Health and Nutrition Examination
Survey. International journal of chronic obstructive pulmonary
disease. 2016;11:3001.
17. Shibata Y, Abe S, Inoue S, et al. Relationship between plasma
fibrinogen levels and pulmonary function in the Japanese population: the
Takahata study. International journal of medical sciences.2013;10(11):1530.
18. Enomoto N, Oyama Y, Enomoto Y, et al. Prognostic evaluation of serum
ferritin in acute exacerbation of idiopathic pulmonary fibrosis.The clinical respiratory journal. 2018;12(8):2378-2389.
19. Bargagli E, Madioni C, Bianchi N, Refini R, Cappelli R, Rottoli P.
Serum analysis of coagulation factors in IPF and NSIP.Inflammation. 2014;37(1):10-16.